Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FBLG
- Price
- 0.25
- Stock movement up
- +0.00 (0.40%)
- Company name
- FibroBiologics, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 16.76M
- Ent value
- 15.33M
- Price/Sales
- -
- Price/Book
- 2.72
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -80.47%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-03-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FBLG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.72 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 66.52M |
| EPS (TTM) | -0.42 |
| FCF per share (TTM) | -0.37 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -671.00K |
| Operating income (TTM) | -16.65M |
| Net income (TTM) | -18.65M |
| EPS (TTM) | -0.42 |
| EPS (1y forward) | -0.41 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.89M |
| Net receivables | 0.00 |
| Total current assets | 6.35M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.67M |
| Total assets | 9.62M |
| Accounts payable | 945.00K |
| Short/Current long term debt | 2.41M |
| Total current liabilities | 1.76M |
| Total liabilities | 3.46M |
| Shareholder's equity | 6.16M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.39M |
| Capital expenditures (TTM) | 262.00K |
| Free cash flow (TTM) | -16.66M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -302.89% |
| Return on Assets | -193.85% |
| Return on Invested Capital | -271.73% |
| Cash Return on Invested Capital | -242.73% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.26 |
| Daily high | 0.26 |
| Daily low | 0.24 |
| Daily Volume | 478K |
| All-time high | 17.50 |
| 1y analyst estimate | 4.75 |
| Beta | -0.67 |
| EPS (TTM) | -0.42 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| FBLG | S&P500 | |
| Current price drop from All-time high | -98.56% | -1.82% |
| Highest price drop | -98.71% | -56.47% |
| Date of highest drop | 31 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -81.30% | -10.84% |
| Avg time to new high | 256 days | 12 days |
| Max time to new high | 512 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
16.76M
Marketcap category
Small-cap
Description
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Employees
15
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page